Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 4/20 | 0.49 |
| ▸ | RAF1 | P04049 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.38 |
| ▸ | TGFBR2 | P37173 | 3/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.37 |
| ▸ | BUB1 | O43683 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30365849 | 1.00 | MET (0.49) | METRAF1DYRK1ATGFBR1TGFBR2 | |
| SCHEMBL25201249 | 0.88 | MET (0.49) | METRAF1DYRK1ATGFBR1TGFBR2 | |
| SCHEMBL30365622 | 0.88 | MET (0.49) | METRAF1DYRK1ATGFBR1TGFBR2 | |
| SCHEMBL26597857 | 0.87 | TGFBR1 (0.51) | METRAF1DYRK1ATGFBR1TGFBR2 | |
| SCHEMBL30365685 | 0.87 | TGFBR1 (0.51) | METRAF1DYRK1ATGFBR1TGFBR2 | |
| SCHEMBL25213270 | 0.79 | TGFBR1 (0.65) | TGFBR1TGFBR2MAPK14BUB1 | |
| SCHEMBL25211887 | 0.78 | TGFBR1 (0.51) | METRAF1TGFBR1TGFBR2MAPK14 | |
| SCHEMBL25249802 | 0.74 | RAF1 (0.51) | METRAF1DYRK1ATGFBR1TGFBR2 | |
| SCHEMBL25217309 | 0.74 | MET (0.49) | METRAF1DYRK1ATGFBR1TGFBR2 | |
| SCHEMBL25207936 | 0.74 | TGFBR1 (0.48) | METRAF1DYRK1ATGFBR1TGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4509122-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2025-02-19 | — | — | EP | disclosed |
| EP-4188930-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | BAYER AG (DE) | 2024-10-23 | — | — | EP | disclosed |
| US-20230391769-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-12-07 | — | — | US | disclosed |
| EP-4188930-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391769-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | CYP11B2, SDHA, UGT2B7 | MET 1000/4885RAF1 2812/4885DYRK1A 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.